{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04849910",
            "orgStudyIdInfo": {
                "id": "VBP101"
            },
            "organization": {
                "fullName": "Vor Biopharma",
                "class": "INDUSTRY"
            },
            "briefTitle": "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS",
            "officialTitle": "A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation",
            "therapeuticArea": [
                "Rare Diseases",
                "Oncology and Hematology"
            ],
            "study": "allogeneic-engineered-hematopoietic-stem-cell-transplant-hct-lacking-the-protein-and-post-hct-treatment-with-mylotarg-for-patients-with-aml-or-mds"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-03-25",
            "studyFirstSubmitQcDate": "2021-04-16",
            "studyFirstPostDateStruct": {
                "date": "2021-04-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vor Biopharma",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).",
            "detailedDescription": "High risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) frequently relapses despite hematopoietic stem cell transplant (HCT). Post-HCT targeted therapy to reduce relapse is limited by toxicity to the engrafted cells. VOR33, an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product, lacking the CD33 protein, is being investigated for participants with CD33+ AML or MDS at high risk for relapse after HCT to allow post-HCT targeting of residual CD33+ acute AML cells using Mylotarg\u2122 without toxicity to engrafted VOR33 cells. Participants will undergo a myeloablative HCT with matched related or unrelated donor CD34+-selected hematopoietic stem and progenitor cells (HSPCs) engineered to remove CD33 expression (VOR33 product). Mylotarg\u2122 will be given after engraftment for up to 4 cycles. The primary endpoint assessing safety of VOR33 will be the incidence of successful engraftment at 28 days. Part 1 of this study will evaluate the safety of escalating Mylotarg\u2122 dose levels to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 will expand the number of participants to evaluate the Mylotarg\u2122 RP2D."
        },
        "conditionsModule": {
            "conditions": [
                "Leukemia, Myeloid, Acute",
                "Myelodysplastic Syndromes"
            ],
            "keywords": [
                "Leukemia",
                "Acute Myeloid Leukemia",
                "AML",
                "Hematopoietic stem cell transplant",
                "HCT",
                "CD33",
                "Allogeneic",
                "Myelodysplastic Syndromes",
                "Myelodysplastic Syndromes with excess blasts",
                "MDS",
                "MDS-EB",
                "Cell therapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "VOR33 infusion followed by Mylotarg Dose Level 1",
                    "interventionNames": [
                        "Biological: VOR33",
                        "Drug: Mylotarg"
                    ]
                },
                {
                    "label": "Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "VOR33 infusion followed by Mylotarg Dose Level 2",
                    "interventionNames": [
                        "Biological: VOR33",
                        "Drug: Mylotarg"
                    ]
                },
                {
                    "label": "Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "VOR33 infusion followed by Mylotarg Dose Level 3",
                    "interventionNames": [
                        "Biological: VOR33",
                        "Drug: Mylotarg"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "VOR33",
                    "description": "Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2",
                        "Cohort 3"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Mylotarg",
                    "description": "Infusion of Mylotarg",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2",
                        "Cohort 3"
                    ],
                    "otherNames": [
                        "gemtuzumab ozogamicin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of neutrophil engraftment",
                    "description": "Cumulative incidence of patients who achieve neutrophil engraftment (first day of 3 consecutive days of absolute neutrophil count (ANC) \u2265500 cells/mm3) by Day 28.",
                    "timeFrame": "Day 28"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to neutrophil engraftment",
                    "description": "Time to neutrophil engraftment after HCT from Day 0; calculated as the first day of 3 consecutive laboratory values obtained on separate days where the ANC is \u2265500 cells/mm3.",
                    "timeFrame": "Up to approximately 28 days"
                },
                {
                    "measure": "Time to platelet recovery",
                    "description": "Time to platelet recovery defined as first day of a sustained platelet count \\>20,000/ \u03bcL with no platelet transfusion in the preceding seven days.",
                    "timeFrame": "Up to approximately 60 days"
                },
                {
                    "measure": "Incidence of acute GVHD Grade (G) G2-G4 and G3-G4",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Incidence of chronic GVHD (all and moderate-severe)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Incidence of primary and secondary graft failure",
                    "description": "Incidence of primary and secondary graft failure measured by day 28 post HCT. Secondary graft failure is defined as initial neutrophil engraftment by Day 28 followed by subsequent decline.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Incidence of toxicities to determine the MTD and RP2D of Mylotarg\u2122",
                    "timeFrame": "Approximately day 60 until 24 months"
                },
                {
                    "measure": "Incidence of transplant-related mortality (TRM) post HCT",
                    "timeFrame": "Day 100, 12 months, 24 months"
                },
                {
                    "measure": "Percentage of CD33-negative myeloid cells",
                    "description": "Percent donor myeloid chimerism and CD33-negative myeloid cells in peripheral blood.",
                    "timeFrame": "Day 28, 60, 100, 180, and Months 12 and 24"
                },
                {
                    "measure": "Relapse-free Survival (RFS)",
                    "description": "Cumulative incidence of RFS",
                    "timeFrame": "Months 12 and 24"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "OS defined as the time from HCT to the date of death from any cause",
                    "timeFrame": "Months 12 and 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Must be \u226518 and \u226470 years of age.\n2. Patients with AML must have one of the following groups of features that are known to be a risk factor for leukemia relapse:\n\n   * BM in morphological remission (\\<5% blasts) with adverse-risk disease related genetics at presentation (according to European Leukemia-Net guidelines \\[ELN, D\u00f6hner 2017\\]), or\n   * Intermediate risk genetics in morphologic remission (\\<5% blasts) with other recognized high risk criteria such as MRD+ following therapy, or\n   * BM with evidence of persistent leukemia 5-10% blasts post induction/salvage therapy. Patients with BM Blast count \\>10% may participate with Sponsor Medical Monitor approval. (Note: these patients may have disease-related genetics of any risk criteria at presentation), or\n   * Any patient in second or greater remission.\n3. Patients with MDS must have all of the following:\n\n   * Previous or current IPSS-R score of High or Very High risk; AND\n   * Previous or current MDS-IB1 or MDS-IB2 per the 2022 WHO criteria (Khoury 2022)\n4. AML sample from the patient must have evidence of CD33 expression (\\>0%)\n5. Candidate for HLA-matched allogeneic HCT using a myeloablative conditioning regimen.\n6. Must have a related or unrelated stem cell donor that is a 8/8 match for HLA-A, -B, -C, and -DRB1.\n7. Must have adequate performance status and organ function as defined below:\n\n   1. Performance Status: Karnofsky score of \u226570.\n   2. Cardiac: left ventricular ejection fraction (LVEF) \u226550%\n   3. Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO), forced vital capacity (FVC), and forced expiratory volume in one second (FEV1) \u226566%.\n   4. Renal: estimated glomerular filtration rate (GFR) \\>60 mL/min\n   5. Hepatic: total bilirubin \\<1.5 \u00d7 ULN, or if \u22651.5 \u00d7 ULN direct bilirubin \\<ULN and ALT/AST \\<1.5 \u00d7 ULN (per institutional criteria).\n\nExclusion Criteria:\n\n1. Prior autologous or allogeneic stem cell transplantation.\n2. Presence of the following disease-related genetics: t(15; 17)(q22; q21), or t(9; 22)(q34; q11), or other evidence of acute promyelocytic leukemia or chronic myeloid leukemia.\n3. Prior treatment with Mylotarg\u2122 (gemtuzumab ozogamicin) in the past 3.5 months.\n4. Active central nervous system (CNS) leukemia.\n5. Patients diagnosed with Gilbert's syndrome.\n6. Uncontrolled bacterial, viral, or fungal infections; or known human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Glen Raffel, MD, PhD",
                    "role": "CONTACT",
                    "phone": "6176556580",
                    "phoneExt": "180",
                    "email": "clinicaltrials@vorbio.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of California San Diego Moores Cancer Center",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92037",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Olivia Nolan",
                            "role": "CONTACT",
                            "phone": "858-246-5794",
                            "email": "ocnolan@health.ucsd.edu"
                        },
                        {
                            "name": "Divya Koura, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                },
                {
                    "facility": "Miami Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33176",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Guenther Koehne, MD, PhD",
                            "role": "CONTACT",
                            "phone": "786-527-8427",
                            "email": "guentherk@baptisthealth.net"
                        },
                        {
                            "name": "Guenther Koehne, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "The University of Kansas Cancer Center",
                    "status": "RECRUITING",
                    "city": "Fairway",
                    "state": "Kansas",
                    "zip": "66205",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Muhammad U Mushtaq, MD",
                            "role": "CONTACT",
                            "phone": "913-945-6594",
                            "email": "mmushtaq@kumc.edu"
                        },
                        {
                            "name": "Muhammad U Mushtaq, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.02223,
                        "lon": -94.6319
                    }
                },
                {
                    "facility": "National Institutes of Health, Clinical Center",
                    "status": "RECRUITING",
                    "city": "Bethesda",
                    "state": "Maryland",
                    "zip": "20892",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nirali Shah, MD, MHSc",
                            "role": "CONTACT",
                            "phone": "240-760-6199",
                            "email": "nirali.shah@nih.gov"
                        },
                        {
                            "name": "Nirali Shah, MD, MHSc",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.98067,
                        "lon": -77.10026
                    }
                },
                {
                    "facility": "Masonic Cancer Center, University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Maakaron, MD",
                            "role": "CONTACT",
                            "phone": "612-273-2800",
                            "email": "bonemarrowtransplant@umn.edu"
                        },
                        {
                            "name": "Joseph Maakaron, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "Washington University School of Medicine Siteman Cancer Center",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maggie Nash",
                            "role": "CONTACT",
                            "phone": "314-273-5936",
                            "email": "nashm@wustl.edu"
                        },
                        {
                            "name": "John DiPersio, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "John Theurer Cancer Center at Hackensack University Medical Center",
                    "status": "TERMINATED",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nurse Navigator",
                            "role": "CONTACT",
                            "phone": "212-342-5162",
                            "email": "cancerclinicaltrials@cumc.columbia.edu"
                        },
                        {
                            "name": "Markus Y Mapara, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Roni Tamari, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3738",
                            "email": "ABMTTrials@mskcc.org"
                        },
                        {
                            "name": "Roni Tamari, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University Hospitals Seidman Cancer Center",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cancer Information Service Line",
                            "role": "CONTACT",
                            "phone": "800-641-2422",
                            "email": "Rose.Purgert@UHhospitals.org"
                        },
                        {
                            "name": "Brenda Cooper, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Fred Hutchinson Cancer Research Center",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Roland Walter, MD, PhD, MS",
                            "role": "CONTACT",
                            "phone": "206-667-3599",
                            "email": "rwalter@fredhutch.org"
                        },
                        {
                            "name": "Roland Walter, MD, PhD, MS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "H\u00f4pital Maisonneuve-Rosemont",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H1T2M4",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Lea Bernard, MD",
                            "role": "CONTACT",
                            "phone": "514-252-3404",
                            "email": "lea.bernard.med@ssss.gouv.qc.ca"
                        },
                        {
                            "name": "Lea Bernard, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000011289",
                    "term": "Preleukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                },
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000011230",
                    "term": "Precancerous Conditions"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Leukemia, Myeloid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Leukemia, Myeloid, Acute",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4084",
                    "name": "Anemia, Refractory, with Excess of Blasts",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14111",
                    "name": "Precancerous Conditions",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Leukemia, Myeloid, Acute",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Leukemia, Myeloid, Acute",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T3991",
                    "name": "Myelodysplastic Syndrome With Excess Blasts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000079982",
                    "term": "Gemtuzumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000922",
                    "term": "Immunotoxins"
                },
                {
                    "id": "D000018796",
                    "term": "Immunoconjugates"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2089",
                    "name": "Gemtuzumab",
                    "asFound": "Mitoxantrone",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M4241",
                    "name": "Immunotoxins",
                    "relevance": "LOW"
                },
                {
                    "id": "M20855",
                    "name": "Immunoconjugates",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}